collection
Collections Most Read Papers - Cancer Scie...

Most Read Papers - Cancer Science & Oncogenesis

Most Read Papers - Cancer Science & Oncogenesis

https://read.qxmd.com/read/38610693/new-insights-into-first-line-therapy-in-diffuse-large-b-cell-lymphoma-are-we-improving-outcomes
#1
REVIEW
Pau Abrisqueta
Diffuse large B-cell lymphoma (DLBCL) is the most prevalent subtype of lymphoma, comprising heterogeneous patient subgroups with distinctive biological and clinical characteristics. The R-CHOP combination (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) has been the standard initial treatment, yielding prolonged remissions in over 60% of patients with advanced-stage disease. Several attempts to enhance the outcomes of this regimen over the last two decades have shown limited success. Various novel therapeutic approaches have recently emerged in lymphoma, demonstrating promising results...
March 27, 2024: Journal of Clinical Medicine
https://read.qxmd.com/read/38602566/heart-failure-with-preserved-ejection-fraction-diagnosis-risk-assessment-and-treatment
#2
REVIEW
Stephan von Haehling, Birgit Assmus, Tarek Bekfani, Elke Dworatzek, Frank Edelmann, Djawid Hashemi, Kristian Hellenkamp, Tibor Kempf, Philipp Raake, Katharina A Schütt, Rolf Wachter, Paul Christian Schulze, Gerd Hasenfuss, Michael Böhm, Johann Bauersachs
The aetiology of heart failure with preserved ejection fraction (HFpEF) is heterogenous and overlaps with that of several comorbidities like atrial fibrillation, diabetes mellitus, chronic kidney disease, valvular heart disease, iron deficiency, or sarcopenia. The diagnosis of HFpEF involves evaluating cardiac dysfunction through imaging techniques and assessing increased left ventricular filling pressure, which can be measured directly or estimated through various proxies including natriuretic peptides. To better narrow down the differential diagnosis of HFpEF, European and American heart failure guidelines advocate the use of different algorithms including comorbidities that require diagnosis and rigorous treatment during the evaluation process...
April 11, 2024: Clinical Research in Cardiology: Official Journal of the German Cardiac Society
https://read.qxmd.com/read/38613911/treatment-of-patients-with-braf-v600e-mutated-metastatic-colorectal-cancer-after-progression-to-encorafenib-and-cetuximab-data-from-a-real-world-nationwide-dataset
#3
JOURNAL ARTICLE
M M Germani, G Vetere, F Santamaria, R Intini, F Ghelardi, M Bensi, A Boccaccino, A Minelli, M Carullo, P Ciracì, A Passardi, S Santucci, R Giampieri, M Persano, E Fenocchio, A Puccini, S Lonardi, F Pietrantonio, L Salvatore, C Cremolini
BACKGROUND: Targeted therapy (TT) with encorafenib and cetuximab is the current standard for patients with BRAFV600E -mutated metastatic colorectal cancer (mCRC) who received one or more prior systemic treatments. However, the median progression-free survival (mPFS) is ∼4 months, and little is known about the possibility of administering subsequent therapies, their efficacy, and clinicopathological determinants of outcome. METHODS: A real-world dataset including patients with BRAFV600E -mutated mCRC treated with TT at 21 Italian centers was retrospectively interrogated...
April 12, 2024: ESMO Open
https://read.qxmd.com/read/37948287/tccc-decision-support-with-machine-learning-prediction-of%C3%A2-hemorrhage-risk-shock-probability
#4
JOURNAL ARTICLE
Christopher Nemeth, Adam Amos-Binks, Gregory Rule, Dawn Laufersweiler, Natalie Keeney, Isaac Flint, Yuliya Pinevich, Vitaly Herasevich
INTRODUCTION: Expected future delays in evacuation during near-peer conflicts in remote locales are expected to require extended care including prolonged field care over hours to days. Such delays can increase potential complications, such as insufficient blood flow (shock), bloodstream infection (sepsis), internal bleeding (hemorrhage), and require more complex treatment beyond stabilization. The Trauma Triage Treatment and Training Decision Support (4TDS) system is a real-time decision support system to monitor casualty health and identify such complications...
November 8, 2023: Military Medicine
https://read.qxmd.com/read/38598794/alectinib-in-resected-alk-positive-non-small-cell-lung-cancer
#5
RANDOMIZED CONTROLLED TRIAL
Yi-Long Wu, Rafal Dziadziuszko, Jin Seok Ahn, Fabrice Barlesi, Makoto Nishio, Dae Ho Lee, Jong-Seok Lee, Wenzhao Zhong, Hidehito Horinouchi, Weimin Mao, Maximilian Hochmair, Filippo de Marinis, M Rita Migliorino, Igor Bondarenko, Shun Lu, Qun Wang, Tania Ochi Lohmann, Tingting Xu, Andres Cardona, Thorsten Ruf, Johannes Noe, Benjamin J Solomon
BACKGROUND: Platinum-based chemotherapy is the recommended adjuvant treatment for patients with resectable, ALK -positive non-small-cell lung cancer (NSCLC). Data on the efficacy and safety of adjuvant alectinib as compared with chemotherapy in patients with resected ALK -positive NSCLC are lacking. METHODS: We conducted a global, phase 3, open-label, randomized trial in which patients with completely resected, ALK -positive NSCLC of stage IB (tumors ≥4 cm), II, or IIIA (as classified according to the seventh edition of the Cancer Staging Manual of the American Joint Committee on Cancer and Union for International Cancer Control) were randomly assigned in a 1:1 ratio to receive oral alectinib (600 mg twice daily) for 24 months or intravenous platinum-based chemotherapy in four 21-day cycles...
April 11, 2024: New England Journal of Medicine
https://read.qxmd.com/read/38527788/recent-advances-in-the-prevention-and-treatment-of-decompensated-cirrhosis-and-acute-on-chronic-liver-failure-aclf-and-the-role-of-biomarkers
#6
REVIEW
Jonel Trebicka, Ruben Hernaez, Debbie Lindsay Shawcross, Alexander L Gerbes
The progression of cirrhosis with clinically significant portal hypertension towards decompensated cirrhosis remains clinically challenging and the evolution towards acute-on-chronic liver failure (ACLF), with one or more extrahepatic organ failures, is associated with very high mortality. In the last decade, significant progress has been made in the understanding of the mechanisms leading to decompensation and ACLF. As portal hypertension advances, bacterial translocation across an impaired gut barrier culminates in endotoxaemia, systemic inflammation and cirrhosis-associated immune dysfunction (CAID)...
March 25, 2024: Gut
https://read.qxmd.com/read/38526023/review-article-recent-advances-in-ascites-and-acute-kidney-injury-management-in-cirrhosis
#7
REVIEW
Danielle Adebayo, Florence Wong
BACKGROUND: Better understanding of disease pathophysiology has led to advances in managing ascites and its associated complications including hepatorenal syndrome-acute kidney Injury (HRS-AKI), especially medicinal and interventional advances. AIM: To review the latest changes in the management of ascites and HRS-AKI. METHODS: A literature search was conducted in Pubmed, using the keywords cirrhosis, ascites, renal dysfunction, acute kidney injury, hepatorenal syndrome, beta-blockers, albumin, TIPS and vasoconstrictors, including only publications in English...
March 25, 2024: Alimentary Pharmacology & Therapeutics
https://read.qxmd.com/read/38582189/stenotrophomonas-maltophilia-contributes-to-smoking-related-emphysema-through-irf1-triggered-panoptosis-of-alveolar-epithelial-cells
#8
JOURNAL ARTICLE
Haibo Xia, Jiaheng Lin, Yue Wang, Jinyan Yu, Hailan Wang, Cheng Cheng, Yi Yang, Tao Bian, Yan Wu, Qizhan Liu
Cigarette smoke (CS), the main source of indoor air pollution and the primary risk factor for respiratory diseases, contains chemicals that can perturb microbiota through antibiotic effects. Although smoking induces a disturbance of microbiota in the lower respiratory tract, whether and how it contributes to initiation or promotion of emphysema are not well clarified. Here, we demonstrated an aberrant microbiome in lung tissue of patients with smoking-related COPD. We found that Stenotrophomonas maltophilia (S...
April 4, 2024: Environmental Pollution
https://read.qxmd.com/read/38059896/the-efficacy-of-metoclopramide-for-gastric-visualization-by-endoscopy-in-patients-with-active-upper-gastrointestinal-bleeding-double-blind-randomized-controlled-trial
#9
JOURNAL ARTICLE
Thanrada Vimonsuntirungsri, Rattikorn Thungsuk, Papatsakorn Nopjaroonsri, Natee Faknak, Rapat Pittayanon
INTRODUCTION: The 2021 American College of Gastroenterology Guidelines suggested using of intravenous erythromycin before endoscopy in patients with upper gastrointestinal bleeding (UGIB) to enhance endoscopic view and reduce the need for repeat endoscopy. Evidence on intravenous metoclopramide, which is more accessible, is scant, especially in patients with active UGIB. This study aimed to evaluate the efficacy of metoclopramide for gastric visualization in patients with active UGIB...
January 5, 2024: American Journal of Gastroenterology
https://read.qxmd.com/read/38586911/essential-thrombocythaemia-a-contemporary-approach-with-new-drugs-on-the-horizon
#10
REVIEW
Francisca Ferrer-Marín, Juan Carlos Hernández-Boluda, Alberto Alvarez-Larrán
Essential thrombocythaemia (ET) is a myeloproliferative neoplasm characterized by an increased risk of vascular complications and a tendency to progress to myelofibrosis and acute leukaemia. ET patients have traditionally been stratified into two thrombosis risk categories based on age older than 60 years and a history of thrombosis. More recently, the revised IPSET-thrombosis scoring system, which accounts for the increased risk linked to the JAK2 mutation, has been incorporated into most expert recommendations...
April 8, 2024: British Journal of Haematology
https://read.qxmd.com/read/38265522/molecular-characteristics-and-improved-survival-prediction-in-a-cohort-of-2023-ependymomas
#11
JOURNAL ARTICLE
Lara C Pohl, Maximilian Leitheiser, Denise Obrecht, Leonille Schweizer, Annika K Wefers, Alicia Eckhardt, Mark Raffeld, Dominik Sturm, Kristian W Pajtler, Stefan Rutkowski, Kohei Fukuoka, Koichi Ichimura, Michael Bockmayr, Ulrich Schüller
The diagnosis of ependymoma has moved from a purely histopathological review with limited prognostic value to an integrated diagnosis, relying heavily on molecular information. However, as the integrated approach is still novel and some molecular ependymoma subtypes are quite rare, few studies have correlated integrated pathology and clinical outcome, often focusing on small series of single molecular types. We collected data from 2023 ependymomas as classified by DNA methylation profiling, consisting of 1736 previously published and 287 unpublished methylation profiles...
January 24, 2024: Acta Neuropathologica
https://read.qxmd.com/read/38532595/guideline-for-laboratory-diagnosis-and-monitoring-of-von-willebrand-disease-a-joint-guideline-from-the-united-kingdom-haemophilia-centre-doctors-organisation-and-the-british-society-for-haematology
#12
JOURNAL ARTICLE
Sean Platton, Peter Baker, Annette Bowyer, Catriona Keenan, Caroline Lawrence, Will Lester, Anne Riddell, Megan Sutherland
No abstract text is available yet for this article.
March 26, 2024: British Journal of Haematology
https://read.qxmd.com/read/38572751/global-cancer-statistics-2022-globocan-estimates-of-incidence-and-mortality-worldwide-for-36-cancers-in-185-countries
#13
JOURNAL ARTICLE
Freddie Bray, Mathieu Laversanne, Hyuna Sung, Jacques Ferlay, Rebecca L Siegel, Isabelle Soerjomataram, Ahmedin Jemal
This article presents global cancer statistics by world region for the year 2022 based on updated estimates from the International Agency for Research on Cancer (IARC). There were close to 20 million new cases of cancer in the year 2022 (including nonmelanoma skin cancers [NMSCs]) alongside 9.7 million deaths from cancer (including NMSC). The estimates suggest that approximately one in five men or women develop cancer in a lifetime, whereas around one in nine men and one in 12 women die from it. Lung cancer was the most frequently diagnosed cancer in 2022, responsible for almost 2...
April 4, 2024: CA: a Cancer Journal for Clinicians
https://read.qxmd.com/read/38555412/allogeneic-hematopoietic-cell-transplantation-for-older-patients-with-aml-with-active-disease-a-study-from-the-acute-leukemia-working-party-of-the-european-society-for-blood-and-marrow-transplantation-ebmt
#14
JOURNAL ARTICLE
Enrico Maffini, Myriam Labopin, Nicolaus Kröger, Jürgen Finke, Matthias Stelljes, Thomas Schroeder, Herman Einsele, Johanna Tischer, Martin Bornhäuser, Wolfgang Bethge, Arne Brecht, Wolf Rösler, Peter Dreger, Kerstin Schäfer-Eckart, Jakob Passweg, Igor Wolfgang Blau, Arnon Nagler, Fabio Ciceri, Mohamad Mohty
Older adults with acute myeloid leukemia (AML) refractory to initial or reinduction chemotherapy have a dismal prognosis if they do not undergo hematopoietic stem-cell transplantation (HCT). However, data assessing HCT outcomes from different donors are scarce. We evaluated results from a retrospective analysis on patients aged ≥70 years, with AML not in remission who received an allogeneic HCT from HLA-matched sibling donor (MSD), HLA-10/10 matched unrelated donor (MUD), or T-cell replete haploidentical (Haplo) donor, from 2010 to 2021, reported to the ALWP-EBMT database...
March 30, 2024: Bone Marrow Transplantation
https://read.qxmd.com/read/38552323/financial-legal-navigation-reduces-financial-toxicity-of-pediatric-and-aya-cancers
#15
JOURNAL ARTICLE
Jean Edward, Kimberly D Northrip, Mary Kay Rayens, Andrea Welker, Rachel O'Farrell, Jennifer Knuf, Haafsah Fariduddin, Julia Costich, John D'Orazio
BACKGROUND: Pediatric and Adolescent and Young Adult (AYA) cancer patients and caregivers are at high risk for financial toxicity and few evidence-based oncology financial and legal navigation programs exist to address it. We tested the feasibility, acceptability, and preliminary effectiveness of FINassist (Financial and Insurance Navigation Assistance), a novel interdisciplinary financial and legal navigation intervention for pediatric oncology patients and caregivers. METHODS: We used a single-arm feasibility and acceptability trial design in the Division of Pediatric Oncology and Hematology and collected pre- and post- intervention surveys to assess changes in financial toxicity (three domains: psychological response/Comprehensive Score for Financial Toxicity [COST], material conditions and coping behaviors), health related quality of life (PROMIS Physical and Mental Health, Anxiety, Depression and Parent Proxy scales), and perceived feasibility, acceptability, and appropriateness...
March 29, 2024: JNCI Cancer Spectrum
https://read.qxmd.com/read/38538796/structural-basis-of-exoribonuclease-mediated-mrna-transcription-termination
#16
JOURNAL ARTICLE
Yuan Zeng, Hong-Wei Zhang, Xiao-Xian Wu, Yu Zhang
Efficient termination is required for robust gene transcription. Eukaryotic organisms use a conserved exoribonuclease-mediated mechanism to terminate the mRNA transcription by RNA polymerase II (Pol II)1-5 . Here we report two cryogenic electron microscopy structures of Saccharomyces cerevisiae Pol II pre-termination transcription complexes bound to the 5'-to-3' exoribonuclease Rat1 and its partner Rai1. Our structures show that Rat1 displaces the elongation factor Spt5 to dock at the Pol II stalk domain...
March 27, 2024: Nature
https://read.qxmd.com/read/38548962/management-and-outcome-of-patients-with-chronic-myeloid-leukemia-in-blast-phase-in-the-tyrosine-kinase-inhibitor-era-analysis-of-the-european-leukemianet-blast-phase-registry
#17
JOURNAL ARTICLE
Annamaria Brioli, Elza Lomaia, Christian Fabisch, Tomasz Sacha, Hana Klamova, Elena Morozova, Aleksandra Golos, Philipp Ernst, Ulla Olsson-Stromberg, Daniela Zackova, Franck E Nicolini, Han Bao, Fausto Castagnetti, Elzbieta Patkowska, Jiri Mayer, Klaus Hirschbühl, Helena Podgornik, Edyta Paczkowska, Anne Parry, Thomas Ernst, Astghik Voskanyan, Elzbieta Szczepanek, Susanne Saussele, Georg-Nikolaus Franke, Alexander Kiani, Edgar Faber, Stefan Krause, Luis Felipe Casado, Krzysztof Lewandowski, Matthias Eder, Peter Anhut, Justyna Gil, Thomas Südhoff, Holger Hebart, Sonja Heibl, Markus Pfirrmann, Andreas Hochhaus, Michael Lauseker
Blast phase (BP) of chronic myeloid leukemia (CML) still represents an unmet clinical need with a dismal prognosis. Due to the rarity of the condition and the heterogeneity of the biology and clinical presentation, prospective trials and concise treatment recommendations are lacking. Here we present the analysis of the European LeukemiaNet Blast Phase Registry, an international collection of the clinical presentation, treatment and outcome of blast phases which had been diagnosed in CML patients after 2015...
March 28, 2024: Leukemia
https://read.qxmd.com/read/38498174/frontline-treatment-of-mantle-cell-lymphoma
#18
JOURNAL ARTICLE
Christine E Ryan, Philippe Armand, Ann S LaCasce
Despite many recent therapeutic advances, mantle cell lymphoma (MCL) remains a largely incurable disease. Treatments for patients with relapsed/refractory (R/R) disease are limited in number and in response durability. Therefore, improving the efficacy of frontline (1L) treatment, and specifically maximizing the duration of first remission, remains of critical importance to obtain favorable long-term outcomes. As 1L treatments become more effective, improving tolerability is also becoming an increasingly realistic goal...
March 18, 2024: Blood
https://read.qxmd.com/read/38540242/co-culture-models-key-players-in-in-vitro-neurotoxicity-neurodegeneration-and-bbb-modeling-studies
#19
REVIEW
Ana Rita Monteiro, Daniel José Barbosa, Fernando Remião, Renata Silva
The biological barriers existing in the human body separate the blood circulation from the interstitial fluid in tissues. The blood-brain barrier (BBB) isolates the central nervous system from the bloodstream, presenting a dual role: the protection of the human brain against potentially toxic/harmful substances coming from the blood, while providing nutrients to the brain and removing metabolites. In terms of architectural features, the presence of junctional proteins (that restrict the paracellular transport) and the existence of efflux transporters at the BBB are the two major in vivo characteristics that increase the difficulty in creating an ideal in vitro model for drug permeability studies and neurotoxicity assessments...
March 12, 2024: Biomedicines
https://read.qxmd.com/read/38551368/world-health-organization-and-international-consensus-classification-of-eosinophilic-disorders-2024-update-on-diagnosis-risk-stratification-and-management
#20
JOURNAL ARTICLE
William Shomali, Jason Gotlib
DISEASE OVERVIEW: The eosinophilias encompass a broad range of non-hematologic (secondary or reactive) and hematologic (primary or clonal) disorders with the potential for end-organ damage. DIAGNOSIS: Hypereosinophilia (HE) has generally been defined as a peripheral blood eosinophil count greater than 1.5 × 109 /L, and may be associated with tissue damage. After the exclusion of secondary causes of eosinophilia, diagnostic evaluation of primary eosinophilias relies on a combination of various tests...
March 29, 2024: American Journal of Hematology
label_collection
label_collection
1133
1
2
2024-04-02 00:25:19
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.